Executive Summary
Real-world tricuspid TEER data confirm that the TRILUMINATE and Tri.Fr trial criteria matter: patients who meet them have roughly half the mortality/rehospitalization of those who don't, yet only about half of real-world T-TEER recipients qualify. A TRIVALVE registry analysis of 664 patients found 46% met TRILUMINATE inclusion/exclusion criteria and 50% met Tri.Fr criteria, with eligible patients showing 12% vs 25% (p=0.028) and 15% vs 22% (p=0.007) event rates respectively. The ESC 2025 Class IIa endorsement of transcatheter tricuspid therapy rests on evidence that maps onto only half the patients being treated — and the other half does substantially worse.
- TAVR care fragmentation — readmission to a non-index facility — occurs in 37.4% of 90-day readmissions and independently raises respiratory, GI, and infectious complications (PLOS ONE, N=55,891).
- Aspirin vs clopidogrel monotherapy after TAVI produced no survival difference over 49 months in a propensity-matched cohort of 141 pairs (AJCD).
- Non-general anesthesia for TAVR matched GA on mortality, stroke, MI, and AKI at one year but reduced 30-day readmission (Journal of Clinical Anesthesia, N=3,586 matched).
- A composite AI-ECG detected prevalent structural heart disease with 71–76% sensitivity across 82,000+ patients and predicted incident SHD (HR 2.75–3.75) (medRxiv preprint).
- TD Cowen reiterated Edwards Buy on TAVR growth ahead of the July 23 earnings print (Investing.com).
What to watch: Edwards Lifesciences Q2 earnings drop July 23 — the TAVR growth trajectory is the single number that will move the sector's re-rating story.
Aortic Valve (TAVR/TAVI)
Three TAVR papers today converge on peri-procedural optimization, not durability — and that distinction matters for how they bear on the SAVR vs TAVR debate. Real-world TriNetX data on 1,793 propensity-matched pairs show regional anesthesia or moderate sedation matches general anesthesia on one-year mortality, stroke, MI, AKI, AF, and vascular complications, while reducing 30-day readmission. The study is hypothesis-generating, non-randomized, and retrospective — the authors say so. ACC/AHA 2020 and ESC 2025 neither endorse nor restrict anesthesia modality for TAVR; neither age threshold (SAVR preferred below 65 per ACC/AHA 2020, below 70 per ESC 2025 at low surgical risk) is touched by anesthesia choice. A two-center propensity-matched analysis (N=141 pairs, retrospective) found aspirin and clopidogrel monotherapy indistinguishable at 49 months, consistent with current guidance but too small and non-randomized to resolve it. A Nationwide Readmissions Database study (2016–2021) shows 37.4% of 90-day TAVR readmissions go to a non-index facility, driving respiratory (AOR 1.20), GI (AOR 1.21), and infectious (AOR 1.17) complications. [NOTABLE] As TAVR volumes expand into lower-risk populations under the ESC 2025 framework, the care coordination gap widens with them. A meta-analysis of 11 studies, 7,119 patients found staged PCI did not reduce overall CI-AKI vs concomitant PCI in TAVR patients but favored the staged approach for stage 3/4 AKI (OR 0.48, p=0.046). The analysis is observational and heterogeneous; an RCT is needed before this changes practice.
Mitral Valve (MitraClip, PASCAL, TMVR)
No published mitral outcomes today. The field surfaces only through a TCTMD live case session on the M3 TMVR device at Sutter Health San Francisco. TMVR remains investigational for most anatomies. The surgical counterpoint is the operative baseline against which every TMVR claim must be measured: ESC 2025 upgraded early MV repair in asymptomatic severe primary MR with ≥3 of AF/SPAP >50/LAVI ≥60/moderate TR to Class I, and elevated TEER in ventricular secondary MR meeting COAPT criteria to Class I, LOE A. ACC/AHA 2020 holds both at Class IIa. Nothing today shifts either position. The growing TMVR pipeline presses into a transcatheter mitral replacement space the field has not yet opened at scale — and the surgical benchmark keeps rising as guideline-endorsed repair rates improve.
Tricuspid Valve (TriClip, TTVR)
The TRIVALVE registry analysis is the day's most important structural finding — and its most cautionary. Among 520–519 real-world T-TEER patients, only 46% met TRILUMINATE inclusion/exclusion criteria and 50% met Tri.Fr criteria. Trial-eligible patients had markedly lower mortality/rehospitalization: 12% vs 25% (p=0.028) for TRILUMINATE criteria; 15% vs 22% (p=0.007) for Tri.Fr criteria. The data are registry-based and non-randomized, but the signal is coherent across two independent trial criteria sets. [NOTABLE] The ESC 2025 Class IIa endorsement of transcatheter tricuspid therapy — built on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — was anchored in populations that represent roughly half of who is actually being treated. The non-trial-eligible half does substantially worse, and no randomized data yet characterize them. ESC 2025 simultaneously elevated symptomatic severe primary TR surgery to Class I and asymptomatic primary TR with RV dilation to Class IIa; ACC/AHA 2020 kept both at IIa/IIb. The TRIVALVE data reinforce the case for stricter patient selection — not abandonment of the therapy, but discipline about who receives it. Abbott's TriClip franchise sits directly in the applicability crosshairs.
Surgical vs. Transcatheter Comparisons
No head-to-head data today. The day's transcatheter findings — TAVR anesthesia optimization, T-TEER applicability, TAVR care fragmentation — all sit downstream of settled indications. None engages the SAVR-vs-TAVR durability debate that separates the ACC/AHA 2020 (SAVR preferred below 65) and ESC 2025 (SAVR preferred below 70 at low surgical risk; TAVR preferred at ≥70 with tricuspid AV and transfemoral access) frameworks. The Edwards earnings print on July 23 will reveal whether the low-risk TAVR expansion the ESC endorsed is translating to unit growth or hitting the ceiling that BAV exclusion and unresolved 10-year durability still impose.
Preprint Highlights
A composite AI-ECG combining LVSD and LVDD models detected prevalent structural heart disease with 71.8–76.1% sensitivity and 70.1–88.3% specificity across Korean and US cohorts totaling 82,368 patients, and predicted incident SHD with HR 3.75 and 2.75 in Korean and UK Biobank cohorts respectively. C-statistics ran 0.69–0.78. The screening angle is real; whether ECG-based stratification changes outcomes requires prospective data. The staged-vs-concomitant PCI meta-analysis is covered above under Aortic.
Device & Technology
A validated FE model of the 27mm Allegra TAV across six annular geometries shows ellipticity and alignment drive leaflet coaptation asymmetry and stress concentration — a mechanistic case for why annular anatomy matters to long-term valve function. Bench data, not clinical outcomes, but directly relevant to the durability question the field cannot yet answer with 10-year trial data. A contemporary review of percutaneous transaxillary access updates the technical framework for large-bore structural interventions when transfemoral access is contraindicated. Heartflow's new AI-powered coronary plaque staging tool extends CT-based decision support into the pre-TAVR workflow where CAD assessment shapes the staged-vs-concomitant PCI question.
Industry & Market
Edwards Lifesciences shares held flat ahead of the July 23 earnings report on continued transcatheter heart valve revenue growth. TD Cowen reiterated its Buy on Edwards on TAVR-driven momentum. Edwards also disclosed $280,000 in fresh lobbying spend — quiet by pharma standards but consistent with a device maker managing the reimbursement conversation as TAVR volumes push into lower-risk populations under the ESC 2025 framework.
Financial Analysis
Edwards trades near mid-range at $84.55 (-0.53%) with the Q2 earnings print due July 23. Consensus expects $0.74 EPS on $1.70B revenue. The clinical context matters: the ESC 2025 age threshold shift (TAVR-preferred at ≥70 vs ACC/AHA's ≥80) has expanded the addressable European market, but the low-risk expansion story is bounded by BAV exclusion, unresolved 10-year durability, and today's TRIVALVE data showing trial applicability in the tricuspid space at roughly 50%. If that pattern holds for TAVR sub-populations, real-world volume growth may lag the guideline-implied ceiling. Medtronic trades at $82.35 (-1.13%), down 17.3% over six months — the forward P/E of 12.86 reflects a market that has priced in cardiovascular pipeline uncertainty. Boston Scientific's 6-month drawdown of -52.7% is the sector's outlier, with strong-buy consensus and a $72.43 target implying a substantial re-rating on execution. Abbott's -7.0% six-month move is muted given its diversified base.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $84.55, -0.53% daily, +0.13% 6-month
- Market cap $48.7B; trailing P/E 45.95; forward P/E 25.15; beta 0.85
- 52-week range $72.3–$96.29
- Analyst target $99.0 (range $84–$110, 25 analysts); Buy
- Next earnings July 23: EPS est $0.74, revenue est $1.70B
- The pure-play TAVR/structural name; earnings this week is the sector-defining print
Medtronic (MDT)
- Close $82.35, -1.13% daily, -17.34% 6-month
- Trailing P/E 22.32; forward P/E 12.86; beta 0.58
- 52-week range $73.31–$106.33
- Analyst target $97.84 (range $78–$121, 25 analysts); Buy
- Next earnings Sep 1: EPS est $1.39, revenue est $9.55B
- Diabetes and cardiovascular revenue holding margins per Ad-hoc-news coverage
Abbott (ABT)
- Close $99.67, -1.96% daily, -7.00% 6-month
- Trailing P/E 32.26; forward P/E 16.43; beta 0.61
- 52-week range $81.97–$137.49
- Analyst target $118.33 (range $92–$135, 24 analysts); Buy
- Next earnings Oct 14: EPS est $1.42, revenue est $13.00B
- TriClip franchise sits in the T-TEER applicability crosshairs today
Boston Scientific (BSX)
- Close $43.19, -1.33% daily, -52.69% 6-month
- Market cap $64.2B; trailing P/E 18.3; forward P/E 11.63; beta 0.58
- 52-week range $42.2–$109.5
- Analyst target $72.43 (range $55–$106, 28 analysts); Strong Buy
- Next earnings July 29: EPS est $0.83, revenue est $5.37B
- The sector's biggest drawdown against strong-buy consensus — either the market is wrong or the sell-side is
Anteris Technologies (AVR.AX)
- Close $11.70, +1.30% daily, +31.31% 6-month
- Market cap $1.1B; forward P/E -5.37; beta 0.73
- 52-week range $4.79–$15.47
- Analyst target $13.0 (single analyst)
- DurAVR next-gen TAV story; still pre-commercial burn
The sector picture: Edwards flat awaiting earnings, Medtronic and Abbott softening, Boston Scientific in deep drawdown against strong buy-side conviction. The dispersion reflects a market that has separated the pure-play structural growth story (EW) from the diversified med-tech names where valve is one line item. Anteris's outperformance sits on next-gen TAV promise, not revenue.
JenaValve Technology, J Valve Technology, and Meril Life Sciences remain private.
Clinical Trial Updates
Aortic
- NCT04011722 — Portico Next Generation Approval Study. Status: Active, Not Recruiting. Phase: N/A. Enrollment: 333. Sponsor: Abbott Medical Devices. Interventions: Portico NG (Navitor) Valve + FlexNav Delivery System; Navitor Titan Valve (35mm) + Large FlexNav Delivery System. The Navitor platform is Abbott's answer to Edwards SAPIEN and Medtronic Evolut — approval readout is the piece Abbott needs to compete on the low-risk TAVR expansion the ESC 2025 endorsed.
Mitral Repair
- NCT07716826 — IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive HCM Treated With Mavacamten. Status: Not Yet Recruiting. Enrollment: 150. Sponsor: French Cardiology Society. Mavacamten's positioning against septal reduction and MV surgery in HOCM continues to evolve — this trial addresses the residual mitral apparatus question the pivotal mavacamten trials did not resolve.
Landmark trials referenced today: TRILUMINATE Pivotal and Tri.Fr provide the applicability framework the TRIVALVE analysis interrogates. TRISCEND II results underpin the transcatheter TV replacement pathway. COAPT and RESHAPE-HF2 remain the anchor for ESC 2025's Class I TEER upgrade in ventricular SMR.
Social & Conference Highlights
TCTMD ran a live case session on the M3 TMVR system from Sutter Health, San Francisco — a reminder that TMVR remains an operator-and-anatomy question, not a mass indication.
Next: Edwards Q2 earnings on July 23 will reveal whether the ESC 2025 age threshold shift is translating to unit volume in the low-risk TAVR expansion — the single number that will move the sector's re-rating story and inform how aggressively the field expects the next ACC/AHA update to close the guideline gap.